Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25533312 | 1.00 | CTSS (0.47) | CTSSCTSKMIFRIPK1ESR1 | |
| SCHEMBL1553363 | 1.00 | CTSS (0.47) | CTSSCTSKMIFRIPK1ESR1 | |
| SCHEMBL28995700 | 0.88 | PPARG (0.45) | CTSSCTSKRIPK1GPR88PPARA | |
| SCHEMBL17619268 | 0.88 | PPARG (0.45) | CTSSCTSKRIPK1GPR88PPARA | |
| SCHEMBL25384144 | 0.87 | RIPK1 (0.43) | CTSSCTSKRIPK1GPR88CA1 | |
| SCHEMBL19580945 | 0.87 | CTSS (0.48) | CTSSCTSKRIPK1 | |
| SCHEMBL13059067 | 0.87 | CTSS (0.48) | CTSSCTSKRIPK1GPR88 | |
| SCHEMBL1554097 | 0.87 | CTSS (0.48) | CTSSCTSKRIPK1 | |
| SCHEMBL14847725 | 0.87 | GAA (0.48) | CTSSCTSKRIPK1PPARAPPARG | |
| SCHEMBL1463347 | 0.87 | CTSS (0.48) | CTSSCTSKRIPK1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-114929689-A | Bcl-2 inhibitors | 百济神州有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| CN-104136441-A | Gonadotropin-releasing hormone receptor antagonists, process for their preparation and pharmaceutical compositions comprising them | SK CHEMICALS CO LTD | 2014-11-05 | — | — | CN | disclosed |
| US-8324398-B2 | Process for the synthesis of biaryl oxazolidinones | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| CN-101910155-A | Be used for the treatment of biphenyl derivatives with histamine-obstacle that the H3 receptor modulators is relevant as histamine-H3 receptor modulators | ARENA PHARM INC | 2010-12-08 | — | — | CN | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1778653-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006022794-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | CTSS 3723/4885CTSK 3513/4885MIF 2369/4885 |
| US-20230348386-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | CTSS 2414/4885CTSK 1972/4885MIF 3872/4885 |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CTSS 320/4885CTSK 817/4885MIF 3/4885 |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | CTSS 1699/4885CTSK 1456/4885MIF 39/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | CTSS 3723/4885CTSK 3513/4885MIF 2369/4885 |
| US-11535593-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | CTSS 2414/4885CTSK 1972/4885MIF 3872/4885 |
| US-11014882-B2 | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | PHGDH, G6PD, PGD | CTSS 2414/4885CTSK 1972/4885MIF 3872/4885 |
| US-20190071400-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | CTSS 2414/4885CTSK 1972/4885MIF 3872/4885 |
| US-20220017464-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | PHGDH, G6PD, PGD | CTSS 2414/4885CTSK 1972/4885MIF 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.